Absci (ABSI) Stock Forecast for 2024, 2025, 2026. Sell or Buy Prediction







A Comprehensive Guide to RoadRunner Auto Transport Services

October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services

If you want to ship your car from one city to another, why not hire the experts to do everything for you? They…
Mastering Trading Indicators: Your Essential Toolkit For Success

October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success

Often investors struggle to identify profitable trades consistently. Trading indicators provide essential data to guide trading decisions. This article explains key indicators and…
Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…

Absci (ABSI) Stock Forecast for 2024, 2025, 2026. Sell or Buy?

Updated: November 14, 2024 (10:22)

Sector: Healthcare

The share price of Absci Corporation (ABSI) now

Latest session on the 13th of November for
Absci Corporation is negative
Trading Volume: 1961486
Open: 3.73 /  High: 3.82 /  Low: 3.13
What analysts predict: $8.29
52-week High/Low: $6.72 / $1.33
50-Day Moving Average: $3.988 — resistance level today
200-Day Moving Average: $4.366 — resistance level today

Analysts predictions

Full report
This Week
Neutral Opinions: Na
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Neutral Opinions: 1
Three Weeks Ago
Neutral Opinions: Na

Are you interested in Absci Corporation stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Absci stock price in 2024, 2025, 2026. How much will one Absci share be worth in 2024 - 2026?

When should I take profit in Absci stock? When should I record a loss on Absci stock? What are analysts' forecasts for Absci stock? What is the future of Absci stock? We forecast Absci stock performance using neural networks based on historical data on Absci stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Absci stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Absci shares. This happens once a day.


Historical and forecast chart of Absci stock

The chart below shows the historical price of Absci stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Absci stock price can be found in the table below.

Long-term forecasts by years.

Absci Corporation Analysts predictions review

As of now, Panda has combed through 1 analytical articles which are directly related to ABSI from the last 30 days. Out of these, 0 clearly showcase a bullish trend, while 0 see a bearish trend as the more likely scenario, and 1 stay neutral.

To identify the dominant trend, we took into account analytical articles from the past 30 days, spanning from Oct 29, 2024 to Oct 29, 2024.

Absci's Pipeline: Balancing Innovative Promise with Financial Pressures

Trend: Neutral
Oct 29, 2024

In the analytical financial article under review, seasoned analyst Richard Durant offers insights into ABSI stock, maintaining a Neutral stance on its potential trajectory. With an impressive tally of 615 publications since joining the platform in 2019, Durant's prolific output underscores his active engagement and expertise in financial analysis. Furthermore, his substantial subscriber base of 7,978 and excellent credibility position, reflective of a high authority rating, signify a deep trust in his balanced and informed viewpoints. His analyses, shaped by years of dedicated study and contribution, provide a reliable perspective for investors navigating ABSI stock, ensuring that readers receive well-considered advice grounded in substantial analytical experience.

Key Theses of the Analysis on Absci

  • Absci's differentiated drug discovery platform has potential to create significant shareholder value long term.
  • The company faces a long and expensive path to prove the effectiveness of its approach.
  • While current cash burn is limited, anticipated increased costs might pressure share price in the future.
  • Absci appears expensive relative to peers due to maintaining market favor despite broader industry pessimism.

Key Factors Influencing ABSI Stock Price

Positive Preclinical Data from ABS-101 program

Significance: 8 out of 10

The positive data announcement contributes to maintaining investor confidence and could lead to higher share prices, despite industry volatility. This strengthens investor interest and reduces the impact of broader industry setbacks.

Collaboration with Nvidia

Significance: 7 out of 10

The association with a leading AI company enhances Absci's credibility and investor appeal, providing a significant reputational boost. This collaboration is perceived as a strategic asset, positively influencing the stock price.

Limited Cash Burn

Significance: 6 out of 10

Current moderate cash burn reassures investors about financial stability in the near term amidst economic uncertainties. However, expected increased expenditures might reduce this comfort level in future evaluations, impacting stock perception.

Comparison to Peers

Significance: 5 out of 10

Absci's premium valuation compared to peers might attract initial investor skepticism, impacting stock sentiment. While it highlights investor confidence, further justifying this valuation could become a pressure point in the near future.

Partnerships and Collaborations

Significance: 7 out of 10

Partnerships with prestigious institutions like Memorial Sloan Kettering Cancer Center bolster Absci's project validation and resource sharing, positively impacting stock value. These partnerships enhance pipeline advancement while controlling costs, providing investor confidence in project fruition.

Cash Position and Future Capital Requirements

Significance: 9 out of 10

Absci's moderate cash position with anticipated future capital requirements could significantly impact share valuations, reflecting investor concerns over potential dilution and financial trajectory. The strategic timing of capital raises will be critical to stock performance in this context.

Review the original Analysis

Commentary

Absci's innovative drug discovery platform is poised to capture attention, bolstered by positive preclinical data and strategic partnerships, including a notable collaboration with Nvidia. These developments are instrumental, reflecting an average influence strength that leans positively in the short term and neutral in the coming month. The immediate 15-day outlook suggests resilience against broader industry trends due to these impactful collaborations, keeping investor confidence buoyed despite prevailing market volatility.

However, this optimism is tempered by the looming challenges of future capital requirements. Absci's current cash position provides temporary respite but anticipated expenses signal forthcoming pressures. Investors must weigh the company's premium valuation against these financial demands, with partnerships aiding in offsetting costs. As such, the valuation sentiment remains mixed, bordered between enthusiasm over strategic moves and caution over fiscal sustainability. The next month could see Absci treading on neutral grounds as it maneuvers through its fiscal realities, setting the stage for carefully strategized capital raises.

Absci's AI-Driven ABS-101: Poised for a Breakthrough in IBD Market

Trend: Strong Bullish
Oct 03, 2024

In reviewing the analytical financial article by Terry Chrisomalis, it's clear that the author maintains a Strong Bullish stance on ABSI stock. Chrisomalis, a seasoned contributor since 2013, has amassed an impressive 1,311 publications, underscoring his prolific nature and dedication to the field. With 12,819 subscribers, he possesses significant popularity, reflecting the collective interest and trust investors place in his insights. Given the high credibility of his viewpoints, as indicated by his impressive publishing track record and extensive tenure, Chrisomalis's analysis and insights carry considerable weight. Readers can confidently rely on his assessment of ABSI stock, taking into account his high authority and consistent engagement with financial analysis and market trends over the past decade.

Key Theses of the Review

  • Absci Corporation's ABS-101 targets IBD using a novel AI-driven approach.
  • The drug aims for unique advantages like de novo antibody creation and dosing flexibility.
  • Global markets for Crohn's Disease and Ulcerative Colitis present significant opportunities.
  • Interim data from the Phase 1 study of ABS-101 is expected in the second half of 2025.

Factors Influencing ABSI Stock Price

Initiation and Interim Data from Phase 1 Study

Significance: 9 out of 10

The successful launch and interim results of the Phase 1 study of ABS-101 could significantly boost investor confidence, leading to a positive impact on stock prices. Considering the innovative AI-driven approach, any early success will position Absci as a leader in the field, motivating stock appreciation.

Market Potential for Crohn's Disease and Ulcerative Colitis

Significance: 8 out of 10

The potential to tap into the combined markets valued at over $32 billion by 2033 underscores a massive revenue opportunity. Positive developments in ABS-101 could capture substantial market share, potentially increasing future earnings and stock valuation.

Financial Position and Funding Requirements

Significance: 7 out of 10

Absci has a decent cash position with $145.2 million as of June 2024, but it anticipates needing further fundraising within 12 months. Future stock dilution depends on share offerings which could temporarily pressure stock prices.

Competitive Environment

Significance: 6 out of 10

With competitors like Merck, Roche, and Sanofi also developing TL1A drugs, obtaining a competitive edge through innovation is vital. Any failure to differentiate its product effectively may hinder market penetration and affect stock performance.

Review the original Analysis

Commentary

Absci Corporation's innovative approach through ABS-101 is shaking up the biopharmaceutical landscape with its AI-driven drug development targeting IBD. On average, the blend of key factors such as the impending interim data release from the Phase 1 study and the massive market potential adds up to make a notable impact on ABSI’s stock trend. The company's technological edge and the anticipation of entering a lucrative $32 billion market for Crohn's Disease and Ulcerative Colitis bolster investor enthusiasm and suggest strong growth potential.

Overall, while Absci faces certain competitive challenges and fundraising needs, its current financial health and pioneering efforts imply a positive trajectory in the immediate future. The average influence of these factors in the next 15 days should suggest a reinforcement of the stock's bullish trend. Looking further out over the coming month, while stock dilution remains a risk, the anticipation surrounding ABS-101’s early results should continue propelling the stock upwards. This makes Absci's stock one to watch closely, especially as it positions itself as a leader in novel TL1A drug development.

Absci Corporation, an artificial intelligence-powered synthetic biology company, offers candidate biologics and production cell lines using an integrated drug discovery platform for partners in the United States. Its integrated drug discovery platform enables biologics to be created by integrating drug discovery and cell line development into a single process. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Trending Themes in the Healthcare Sector

Absci daily forecast for a month

Date Target Pes. Opt. Vol., %
Nov 16 3.35 3.24 3.46 6.95
Nov 17 3.29 3.23 3.40 5.08
Nov 18 3.32 3.23 3.41 5.62
Nov 19 3.34 3.21 3.42 6.56
Nov 20 3.52 3.42 3.66 6.99
Nov 21 3.42 3.25 3.55 9.14
Nov 22 3.51 3.41 3.61 5.99
Nov 23 3.58 3.51 3.63 3.49
Nov 24 3.57 3.49 3.62 3.61
Nov 25 3.53 3.44 3.60 4.56
Nov 26 3.42 3.37 3.53 4.68
Nov 27 3.51 3.43 3.67 7.06
Nov 28 3.50 3.44 3.62 5.00
Nov 29 3.43 3.38 3.60 6.46
Nov 30 3.56 3.46 3.63 4.81
Dec 01 3.51 3.35 3.68 9.67
Dec 02 3.66 3.58 3.81 6.51
Dec 03 3.79 3.61 3.91 8.06
Dec 04 3.68 3.62 3.76 3.78
Dec 05 3.70 3.60 3.85 6.77
Dec 06 3.72 3.63 3.85 6.15
Dec 07 3.56 3.47 3.69 6.27
Dec 08 3.72 3.55 3.77 6.22
Dec 09 3.92 3.78 4.01 6.16
Dec 10 3.90 3.72 4.07 9.57
Dec 11 4.02 3.85 4.18 8.46
Dec 12 4.14 4.07 4.28 5.19
Dec 13 4.15 4.08 4.24 3.85
Dec 14 3.98 3.88 4.15 7.09
Dec 15 3.85 3.73 3.95 5.94

Absci Daily Price Targets


Absci Stock Forecast 11-16-2024.

Forecast target price for 11-16-2024: $3.35.
Positive dynamics for Absci shares will prevail with possible volatility of 6.494%.
Pessimistic target level: 3.24
Optimistic target level: 3.46

Absci Stock Forecast 11-17-2024.

Forecast target price for 11-17-2024: $3.29.
Negative dynamics for Absci shares will prevail with possible volatility of 4.832%.
Pessimistic target level: 3.23
Optimistic target level: 3.40

Absci Stock Forecast 11-18-2024.

Forecast target price for 11-18-2024: $3.32.
Positive dynamics for Absci shares will prevail with possible volatility of 5.320%.
Pessimistic target level: 3.23
Optimistic target level: 3.41

Absci Stock Forecast 11-19-2024.

Forecast target price for 11-19-2024: $3.34.
Positive dynamics for Absci shares will prevail with possible volatility of 6.160%.
Pessimistic target level: 3.21
Optimistic target level: 3.42

Absci Stock Forecast 11-20-2024.

Forecast target price for 11-20-2024: $3.52.
Positive dynamics for Absci shares will prevail with possible volatility of 6.529%.
Pessimistic target level: 3.42
Optimistic target level: 3.66

Absci Stock Forecast 11-21-2024.

Forecast target price for 11-21-2024: $3.42.
Negative dynamics for Absci shares will prevail with possible volatility of 8.373%.
Pessimistic target level: 3.25
Optimistic target level: 3.55

ABSI (ABSI) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Dec. 3.04 2.72 3.19 14.79

Absci forecast for this year


Absci Stock Prediction for Dec 2024

An downtrend is forecast for this month with an optimal target price of $3.04109. Pessimistic: $2.72. Optimistic: $3.19



Absci (ABSI) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 3.65 3.42 3.82 10.44
Feb 3.45 2.90 3.98 27.26
Mar 2.86 2.56 3.32 23.14
Apr 2.30 1.95 2.48 21.43
May 2.52 2.35 2.88 18.23
Jun 2.66 2.34 2.87 18.32
Jul 2.78 2.51 3.15 20.40
Aug 2.73 2.33 2.89 19.48
Sep 3.12 2.64 3.62 26.98
Oct 2.97 2.85 3.25 12.30
Nov 2.81 2.36 2.96 20.35
Dec 2.66 2.37 3.00 20.74

Absci (ABSI) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 2.43 2.09 2.63 20.38
Feb 2.26 1.91 2.55 24.94
Mar 2.54 2.41 2.84 15.19
Apr 2.58 2.45 2.74 10.51
May 2.71 2.54 3.09 17.67
Jun 2.68 2.52 2.95 14.69
Jul 2.89 2.68 3.15 14.83
Aug 2.86 2.61 3.12 16.21
Sep 2.92 2.48 3.27 24.15
Oct 2.90 2.57 3.15 18.37
Nov 3.47 3.10 4.03 23.14
Dec 3.47 2.96 4.00 25.90

Absci information and performance

Absci Address

18105 SE MILL PLAIN BLVD, VANCOUVER, WA, US

Market Capitalization: 486 020 000 $

Market capitalization of the Absci Corporation is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ABSI shares in the company outstanding by the market price of one share.

EBITDA: -83 964 000 $

EBITDA of Absci is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: None

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -0.93

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.623
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 86.59

Enterprise Value (EV) /Revenue

EV To EBITDA: -0.391

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 113556000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.